Table 1. Receptor Interaction Profiles for LSD and Other Classic Serotonergic Hallucinogens at Human Receptors.
LSDa | Psilocinb | DMTb | Mescalinea | ||
---|---|---|---|---|---|
5-HT1A | Receptor binding Ki±SD (μM) | 0.003±0.0005 | 0.123±0.02 | 0.075±0.02 | 4.6±0.4 |
5-HT2A | Receptor binding Ki±SD (μM) | 0.004±0.001 | 0.049±0.01 | 0.237±0.04 | 6.3±1.8 |
5-HT2A | Activation potency EC50±SD (μM) | 0.261±0.15 | 0.721±0.55 | 0.076±0.03 | 10±1.8 |
5-HT2A | Activation efficacy % maximum±SD | 28±10 | 16±8 | 40±11 | 56±15 |
5-HT2B | Activation potency EC50±SD (μM) | 12±0.4 | >20 | 3.4±3.2 | >20 |
5-HT2B | Activation efficacy % maximum±SD | 71±31 | 19±6 | ||
5-HT2C | Receptor binding Ki±SD (μM) | 0.015±0.003 | 0.094±0.009 | 0.424±0.15 | 17±2.0 |
α2A | Receptor binding Ki±SD (μM) | 0.67±0.18 | 6.7±1.1 | 1.3±0.2 | >15 |
α1A | Receptor binding Ki±SD (μM) | 0.012±0.002 | 2.1±0.01 | 2.1±0.4 | 1.4±0.2 |
D1 | Receptor binding Ki±SD (μM) | 0.31±0.09 | >14 | 6.0±0.9 | >14 |
D2 | Receptor binding Ki±SD (μM) | 0.025±0.0004 | 3.7±0.6 | 3.0±0.4 | >10 |
D3 | Receptor binding Ki±SD (μM) | 0.10±0.01 | 8.9±0.8 | 6.3±2.1 | >17 |
H1 | Receptor binding Ki±SD (μM) | 1.1±0.2 | 1.6±0.2 | 0.22±0.03 | >25 |
TAAR1c | Activation potency EC50±SD (μM) | >20 | >30 | >10 | >10 |
NET | Receptor binding Ki±SD (μM) | >30 | 13±1.7 | 6.5±1.3 | >30 |
NET | Inhibition potency IC50 (μM) (95% CI) | >100 | 14 (10–19) | 3.9 (2.8–5.3) | >100 |
DAT | Receptor binding Ki±SD (μM) | >30 | >30 | 22±3.9 | >30 |
DAT | Inhibition potency IC50 (μM) (95% CI) | >100 | >100 | 52 (37–72) | >100 |
SERT | Receptor binding Ki±SD (μM) | >30 | 6.0±0.3 | 6.0±0.6 | >30 |
SERT | Inhibition potency IC50 (μM) (95% CI) | >100 | 3.9 (3.1–4.8) | 3.1 (2.4–4.0) | >100 |
Dosed | Mg | 0.1 | 12 | 40 | 300 |
Abbreviations: DAT, dopamine transporter; NET, norepinephrine transporter; SERT, serotonin transporter.
All data were generated using the same assays across substances to allow for direct comparisons.
Estimated average psychoactive dose in humans from Passie et al, 2008 and Nichols, 2004.